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Abstract: Diabetes mellitus is characterized by high blood glucose level with typical 
manifestations of thirst, polyuria, polydipsia, and weight loss. It is caused by defects in insulin-
mediated signal pathways, resulting in decreased glucose transportation from blood into muscle 
and fat cells. The major risk is vascular injury leading to heart disease, which is accelerated 
by increased lipid levels and hypertension. Management of diabetes includes: control of blood 
glucose level and lipids; and reduction of hypertension. Dietary intake of beta-glucans has been 
shown to reduce all these risk factors to beneﬁ  t the treatment of diabetes and associated com-
plications. In addition, beta-glucans also promote wound healing and alleviate ischemic heart 
injury. However, the mechanisms behind the effect of beta-glucans on diabetes and associated 
complications need to be further studied using pure beta-glucan.
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Introduction
Diabetes mellitus (diabetes) is a chronic condition characterized by high blood glucose 
level (hyperglycemia) with typical manifestations of thirst, polyuria, polydipsia, and 
weight loss (Rother 2007). There are 171 million people worldwide suffering from 
diabetes in 2000 according to World Health Organization (WHO) statistics and this 
number would be more than double by 2030 (WHO 2008). The disease is responsible 
for 3.2 million deaths every year (WHO 2008). Three types of diabetes have been 
described. Type 1 is caused by T-cell mediated autoimmune destruction of islet insulin-
secreting beta-cells (Rother 2007). Type 2 is characterized by the resistance to insulin 
with both hyperglycemia and hyperinsulinemia followed by the deﬁ  ciency of insulin. 
Type 3 specially refers to that in pregnancy, which has both decreased insulin and 
increased resistance to insulin (Schinner et al 2005; Carpenter 2007; Kreier et al 2007). 
Among them, type 2 diabetes accounts for 90% of total incidence of diabetes (WHO 
2008). Furthermore, prevalence of type 2 diabetes is increasing due to population 
growth, ageing, unhealthy diets, obesity, and sedentary lifestyles (James 2008). At 
present, diabetes is treated by injection of insulin (type 1) and combined with diet, 
exercise, weigh loss, and diabetic drugs (type 2). However, the control of diabtes 
associated mortality and decreased life quality is not satisfactory.
Beta-glucans are polysaccharides consisting of glucose residue jointed by beta link-
age (Chen and Seviour 2007). They are found at a high level in the cell wall of fungi, 
yeast, oat, barley, as well as bacteria (McIntosh et al 2005). Their structures are diverse 
with fungal beta-glucans being beta-1,3 linkage branched by 1,6 while oat and barley 
beta-glucans linked by linear 1,3 and 1,4 bonds (Chen and Seviour 2007; Sadiq Butt 
et al 2008). However, beta-glucans are also excreted into growth medium, and this could 
facilitate puriﬁ  cation and production (Schmid et al 2001). Natural products containing 
beta-glucans have been used for thousands of years for the beneﬁ  ts of human health, 
but beta-glucans were only identiﬁ  ed as active components recently (Lucas et al 1958; Vascular Health and Risk Management 2008:4(6) 1266
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Williams and Di Luzio 1980). Since then, they have been 
studied extensively for immune stimulation effects and 
developed for the treatment of several diseases including 
cancer, infectious diseases (Chen and Seviour 2007). Studies 
also showed that beta-glucans have great potential for the 
treatment of diabetes and associated cardiovascular diseases. 
The foods containing beta-glucans have been used for clini-
cal trial in the treatment of diabetes. In this review, we will 
summary the possible mechanisms for beta-glucans in the 
treatment of diabetes and the prevention of its most severe 
complication of diabetes: cardiovascular risks.
The pathogenesis of diabetes 
and cardiovascular risks
Diabetes is caused by a defect in insulin secretion or insulin 
action. Insulin is the main hormone regulating glucose uptake 
from blood into muscle and fat cells (Schinner et al 2005; 
Lanner et al 2008). It binds to insulin receptor, which is com-
posed of two extracellular alpha and two transmembrane beta 
subunits. After binding of insulin to extracellular subunit, the 
intracellular subunit tyrosine kinase domain will be activated 
(Czech and Corvera 1999). Consequently, four members 
of insulin receptor substrate family (IRS1-4) are activated. 
IRS-proteins in turn activates PI3K/Akt pathway, which is 
a critical signal pathway regulating many cellular functions 
such as apoptosis, cell growth (Manning and Cantley 2007; 
Asano et al 2007; Chen 2008; Chen and McMillan 2008). 
The pathway also regulates glucose transporter 4 (GLUT4) 
to relocate it to cell surface for the transportation of glucose 
into cells (Watson and Pessin 2001). The importance of 
PI3K/Akt was demonstrated by the fact that overexpres-
sion of constitutively active, membrane-targeted PI3K 
component p110α increased the translocation of GLUT4 to 
cell surface and increases glucose transportation into cells, 
irrespective of the presence of insulin (Okada et al 1994; 
Katagiri et al 1996; Martin et al 1996). Activation of PI3K 
also leads to glycogen synthesis in the liver to reduce blood 
glucose levels (Shepherd et al 1995; Sutherland et al 1995; 
Gabbay et al 1996). Recently it has been also shown that 
stimulation of PI3K downstream protein Akt2 activity is 
also sufﬁ  cient for the GLUT4 translocation (Ng et al 2008). 
The defects in insulin signal pathways caused either by the 
insufﬁ  ciency of insulin or the resistance to insulin play a 
central role in all forms of diabetes. It has been found that 
PI3K/Akt pathway is abnormal in diabetes patients (Asano 
et al 2007). In Zucker fatty rat, a model of early-stage type 2 
diabetes induced by overeating and overwight, IRS-1 and 
IRS-2 mRNA was decreased with corresponding decrease 
of PI3K activity (Anai et al 1998). Responses of PI3K /Akt 
activity to insulin-stimulation was also severely impaired 
in the livers of diabetic (ob/ob) mice and Zucker fatty rats 
(Folli et al 1993).
Diabetes has a 2-fold higher death rate than in the non-
diabetes population (Fox et al 2004). Most risks of diabetes 
are from its complications that often result in death. Acute 
complications include hypoglycemia, ketoacidosis, and non-
ketotic hyperosmolar coma while chronic complications are 
cardiovascular diseases (CVD), chronic renal failure, retinal 
damage, nerve damage, and poor healing (Greenhalgh et al 
1990). Due to the use of insulin and the control of blood 
glucose level, the likelihood of death caused by acute com-
plications have been greatly reduced (Siperstein 1992). Thus, 
chronic complications are main danger in diabetes.
Chronic complications of diabetes are catalogued into 
microvascular diseases including diabetic retinopathy, 
nephropathy, and neuropathy; and atherosclerotic mac-
rovascular diseases including ischemic heart disease and 
cerebrovascular and peripheral vascular disease (Klein 
1995). When diagnosed as diabetes, one third of patients 
have already some forms of diabetic retinal lesions (Stolk 
et al 2008), which is the most common cause of blindness in 
middle aged-subjects (Frank 2004).There are 25% of patients 
with nephropathy after 10 years of diagnosis and it is the 
most common reason for renal failure (Gross et al 2005; 
Stolk et al 2008). Diabetes also causes a high prevalence 
of CVD (Stamler et al 1993). The relative risk for CVD in 
patients with diabetes is 2–4 times greater than those without 
diabetes (Fox et al 2004). Diabetes patients with CVD events 
have poor prognoses with 2–3 times greater mortality than 
those patients without diabetes (Fox et al 2004). Thus, CVD 
is responsible for a majority of the morbidity and mortality 
in diabetes (50%–80%) (Kannel and McGee 1979; Pyorala 
et al 1987; Haffner et al 1998). It has been demonstrated that 
combination of diabetes and other CVD risk factors such as 
hypertension and dyslipidemia resulted in higher risk than 
either risk factor along (Goff et al 2007). Thus, the key in 
the treatment of diabetes is to prevent the death caused by 
diabetes-associated CVD.
The management of risk factors including hyperglycemia, 
hypertension, and hyperlipidemia is critical to reduce dia-
betes associated CVD death. The importance for glucose in 
control of diabetes associated complications is demonstrated 
by the fact that each 1% increase in glycosylated hemoglobin 
increases the risk for CVD by approximately 18% (Goff et al 
2007). Randomized trials also have shown that lowering 
LDL cholesterol reduces CVD event rates by 17%–43% in Vascular Health and Risk Management 2008:4(6) 1267
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patients with diabetes and reducing systolic blood pressure 
to 140 mm Hg results in 30%–60% reductions in CVD 
events (Goff et al 2007). Beta-glucans have been tested to 
be effective in lowing blood glucose concentrations and 
decreasing hyerlipidemia and hypertension (Kim et al 2005; 
Goff et al 2007). It may provide another approach to cure 
diabetes.
The effects of beta-glucans 
on the blood glucose concentration 
and the responsible mechanisms
Both oat and fungal beta-glucans reduce blood glucose 
concentrations after oral administration in animal experiments 
and clinical trials (Lo et al 2006). In diabetic rats, orally 
ingested fruiting bodies and the acidic polysaccharide of both 
Tremella mesenterica and T. aurantia reduced blood glucose 
concentrations (Kiho et al 1995). A crude exopolysaccharide 
produced from submerged mycelial cultures of Phellinus 
baummi also exhibited hypoglycemic effects in stretozotocin-
induced diabetic rats (Kiho et al 2000). In genetically diabetic 
mice, oral administration of 20% whole mushroom maitake 
powder and its chemically derived fractions prevented an 
increase in blood glucose levels by increasing insulin sensi-
tivity (Mayell 2001). Another beta-glucan prepared by hot 
water extraction of Agaricus blazei basidiocarps showed 
antihyperglycemic, antihypertriglyceridaemic, antihypercho-
lesterolemic and antiarteriosclerotic activity in diabetic rats 
(Kim et al 2005). All of these studies have used impure beta-
glucans and thus the active component was not identiﬁ  ed. 
However, the preparations from Agaricus blazei basidiocarps 
were digested by an endo beta-(1-6)-glucanase from Bacillus 
megaterium and the resulting di- and tri-saccharides had 
doubled the antidiabetic activities shown by the parent beta-
glucans, which indicates that their derived oligosaccharides 
are the effective agents (Kim et al 2005).
Oat beta-glucans have been used in several clinical trials 
to reduce glucose. Studies showed that oat beta-glucan 
lowered postprandial glycemia (Tappy et al 1996; Jenkins 
et al 2002). It was also shown that oat bran ﬂ  our was more 
effective than oat bran crisp explained by the three times 
higher of beta-glucan content in oat bran ﬂ  our (Saris 2003; 
Tapola et al 2005). The problem is also that no puriﬁ  ed beta-
glucan whose chemical structure has been fully characterized 
has yet been tested against diabetes. Consequently, the need 
is to clarify the structural features required and to identify the 
nature of the beta-glucan binding receptors related to their 
antidiabetes activities.
The effect of beta-glucans to reduce blood glucose could 
be mediated possibly by delaying stomach emptying so that 
dietary glucose is absorbed more gradually (Kiho et al 1995). 
After ingestion of the oat (bran ﬂ  our or crisp), the blood 
glucose levels were lower at 15, 30, and 45 min but higher 
at 90 min after 12.5 g glucose loading (Tapola et al 2005). 
Thus, the peak level is much smoothed and the shape of the 
plasma glucose response curve is much ﬂ  atter (Tapola et al 
2005). These changes reduce the feeling of hunger caused 
by rapid decrease in blood glucose (Ludwig 2003; Saris 
2003). Thus, beta-glucans may decrease appetite and reduce 
food intake.
Another possible mechanism for beta-glucans to reduce 
blood glucose level is mediated by signal pathway through 
PI3K/Akt activation. Decreased PI3K/Akt activity has been 
shown to play a key role in the pathogenesis of diabetes. 
Beta-glucans have been demonstrated to increase PI3K/Akt 
through several receptors (Hsu et al 2002; Chen and Seviour 
2007). These receptors stimulated by beta-glucans include 
Dectin-1, complement receptor 3, lactosylceramide, scav-
enger and toll like receptors; each induces speciﬁ  c signal 
pathways. The interaction between beta-glucans and their 
receptors has been reviewed in detail (Brown 2006; Chen 
and Seviour 2007). The most relevant fact is that adminis-
tration of beta-glucans could restore decreased PI3K/Akt in 
diabetes. For example, zymosan and mushroom extract have 
been shown to activate PI3K/Akt pathway mediated by syk 
kinase (Hiller et al 2000; Li et al 2006; Lee et al 2008). These 
beta-glucans can bind to dectin-1 receptor to stimulate the 
signal pathway (Underhill et al 2005; Trinidad et al 2006; 
Brown 2006; Olsson and Sundler 2007). Another beta-glucan 
lentinan binds to scavenger receptors which can also activate 
src tyrosine kinase and PI3K/Akt pathway (Rice et al 2002; 
Mineo et al 2003). However, how it works in diabetes is not 
studied. It will be interesting to test if beta-glucans could 
restore PI3K/Akt activity in diabetes animal models.
Reduction of blood cholesterol level
Diabetes associated dyslipidemia is a major risk factor for 
CVD (Turner et al 1998). The dyslipidemia is caused either 
by insulin resistance or adipocytokines. In diabetes, adipose 
cells are insulin resistance, thus, insulin-mediated uptake of 
free fatty acids in skeletal muscle is impaired. Increased cir-
culating free fatty acids ﬂ  ux to the liver, resulting in increased 
triglyceride synthesis and the assembly of very low-density 
lipoprotein (VLDL) (Assmann et al 1997; Jeppesen et al 
2003; Hobbs 2006). Thus, the characteristics of dyslipid-
emia in the patients with diabetes is hypertriglyceridemia. Vascular Health and Risk Management 2008:4(6) 1268
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Hyperglycemia and low insulin may also contribute to VLDL 
production (Hobbs 2006). In diabetes, adiponectin is reduced, 
which increases muscle free fatty acid uptake and reduce 
plasma free fatty acid level (Yamauchi et al 2001; Faraj et al 
2004). This mechanism is independent of insulin-resistance 
(Tschritter et al 2003; Schulze et al 2004). In addition, high-
density lipoprotein (HDL) may also decrease (Harris 1991; 
Laakso 1996).
Beta-glucan has been shown to decrease LDL choles-
terol and increase HDL to alleviate possibly dyslipidemia 
and reduce CVD (Anderson 1995; Reyna-Villasmil et al 
2007; Kapur et al 2008). Oats were ﬁ  rst found to have a 
cholesterol-lowering effect and the active component was 
identiﬁ  ed as beta-glucans (Kerckhoffs et al 2002). Oats 
reduced both serum total choleterol and LDL cholesterol 
compared with control (Davidson et al 1991; Van Horn 
et al 1991; Gerhardt and Gallo 1998; Kerckhoffs et al 2003; 
Karmally et al 2005; Naumann et al 2006; Reyna-Villasmil 
et al 2007; Theuwissen and Mensink 2007). In 20 hypercho-
lesterolemic male patients, oat bran was shown to be better 
than wheat bran in lowing choleterol (Anderson et al 1991). 
Barley has also been shown to have a similar effect (Davy 
et al 2002; Behall et al 2004; Shimizu et al 2008). Although 
reduced LDL in diabetes has been shown to decrease CVD 
incidence by 25%–50%, oat and barley beta-glucans do not 
reduce triglyceridemia (Collins et al 2003; Colhoun et al 
2004). Thus, it will be needed to further characterize lipid 
alteration by beta-glucans in diabetes. There is possibility that 
combinational use of beta-glucans with other ﬁ  bers, which 
decrease triglyceride such as a corn ﬁ  ber, α-cyclodextrin 
(trade name FBC) could produce better treatment effect 
(Artiss et al 2006).
Obesity is closely related with diabetes and responsible for 
increased number of diabetes in recent years (Mokdad et al 
2003; Fox et al 2006; Hoenig 2008). Several factors in obesity 
including hyperlipidemia, hyperinsulinemia, hyperleptinemia, 
and insulin resistance could contribute to the development of 
type 2 diabetes (Olefsky 1981; Kissebah et al 1989). Obesity 
has been associated with increased triglyceride, VLDL, total 
cholesterol, and decreased HDL and thus, is also a cause of 
CVD (Denke et al 1994). Administration of oat and barley 
may help to reduce appetite and weight gain. Many studies 
have shown beta-glucans reduced body weight (Artiss et al 
2006; Reyna-Villasmil et al 2007). For example, Sanchez and 
colleagues (2008) showed the lowing body weight effect of 
oat bran beta-glucan at the concentration of 10%. In a clinical 
trial, barley beta-glucan reduced LDL, total cholesterol, 
waist circumference and visceral fat (Shimizu et al 2008). 
However, controversial results have also been presented. 
In a randomized single blinded crossover study, Keogh and 
colleagues (2007) found that soluble ﬁ  bre and amylose from 
barley Himalaya 292 increased subsequent energy intakes 
rather than reduce although it decreased blood glucose and 
insulin levels. They have also reported that barley beta-glucan 
was not effective on LDL (Keogh et al 2003). This could 
be due to lower beta-glucan contents used or different 
properties of beta-glucans in different preparation. Recent 
trials by Shimizu and colleagues (2008) also showed that 7.0 g 
beta-glucan from barley per day for 12 weeks caused marked 
decrease in LDL cholesterol. Therefore it is important to study 
speciﬁ  c effects for structurally different beta-glucans.
The mechanism for beta-glucans to lower LDL is consid-
ered to be mediated by bile acids binding property of beta-
glucans. Therefore beta-glucans increase exclusion of bile 
acids (Lia et al 1995; Marlett 1997; Ellegard and Andersson 
2007), and this in turn activates choleterol 7α-hydroxylase 
and upregulates low-density lipoprotein receptor (LDLR) and 
thus increase the transport of LDL into hepatocytes and the 
conversion of cholesterol into bile acids (Nilsson et al 2007). 
Other soluble dietary ﬁ  bres that are resistant to digestion by 
human enzymes such as pectins, guar gums, psyllium can 
also have similar effects (Anderson et al 1990; Anderson 
1995). The advantages for beta-glucans are that they exhibit 
high viscosities at very low concentration (1%) and are stable 
with pH (Sadiq Butt et al 2008). The viscosity determined 
by water solubility and molecular weight has been shown to 
affect the hypocholesterolemic effect of beta-glucans (Sadiq 
Butt et al 2008). Thus, different structure of beta-glucans 
may have different properties to cause viscosity. Some beta-
glucans may have no effects. It is important to characterize 
what sort of structure features are essential for lowering lipids 
and antidiabetic effects. There is possibility to modulate the 
synthesis of beta-glucans to increase their effect as the suc-
cessful alteration of the resistant starch by siRNA interference 
of starch-branching enzyme (SBE) II (SBEIIa and SBEIIb) in 
wheat has been used (Regina et al 2006). In addition, Oat and 
barley beta-glucans have also been shown to be fermented by 
human fecal microbiota to produce short-chain fatty acids, 
which have also hypocholesterolemic effect (Han et al 2004; 
Drzikova et al 2005; Alminger and Eklund-Jonsson 2008; 
Hughes et al 2008).
The effects of beta-glucans 
on hypertension
Hypertension is a risk factor in diabetes and diabetes itself can 
increase hypertension (Klag et al 1996; Martin et al 1996). Vascular Health and Risk Management 2008:4(6) 1269
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Beta-glucan has been shown to be able to reduce hypertension. 
In genetically modeled rats with spontaneous hypertension 
(SHR), a diet containing 5% Shiitake (Lentinus edodes) or mai-
take (Grifola frondosa) caused a decrease in the mean systemic 
blood pressure (Kabir et al 1987, 1988; Kabir and Kimura 
1989). Moreover, consumption of whole maitake basidiocarps 
and the water-soluble extract also led to a decrease in blood 
pressure in Zuker fatty rats, a diabetes rat model (Talpur et al 
2002a, 2002b, 2003).
A clinical trial with food containing oat beta-glucan 
showed it reduced blood pressure in the subjects with body 
mass index above medians (31.5 kg/m2) (Maki et al 2007). 
This is further demonstrated by another trial that also 
showed effective role of oat (He et al 2004). However, no 
pure beta-glucan has been used for these studies and thus, 
it is difﬁ  cult to identify which components are effective. 
Other components from mushroom have also been shown 
to decrease blood pressure such as pepetides (Talpur et al 
2003; Hyoung Lee et al 2004).
Increase wound healing
Vascular injury may contribute to the pathogenesis of CVD 
(Liuba and Pesonen 2005; Kibos et al 2007). Beta-glucan 
such as zymosan has been shown to be beneﬁ  cial in wound 
healing (Kenyon and Michaels 1983; Browder et al 1988). 
It may increase collagen synthesis (Portera et al 1997; Wei 
et al 2002). The study has shown that beta-glucan can help 
the healing of wound in db/db mice (Berdal et al 2007). This 
is related beta-actin activation of macrophage. There is also 
possibility that beta-glucan could help the healing of vascular 
injury. But no such experiments have been performed.
In addition, cardiomyopathy is 75% more in diabetes 
patients (Bertoni et al 2003) and could be caused by insulin 
resistance in diabetes (Karnik et al 2007). It is also caused 
by the impaired PI3K/Akt pathway (Shulman 2000; Kim 
et al 2001). Insulin sensitizer has been demonstrated to be 
beneﬁ  cial (Sasaki et al 2007). Thus, beta-glucan induction 
of PI3K/Akt to sensitise insulin could be important for the 
prevention of cardiomyopathy in diabetes. Furthermore, 
activated Akt also increases cell survival (Hsu et al 2002). 
Indeed, most of cardiomyopathy is ischemic (Frustaci et al 
2000; Domanski et al 2003). Beta-glucans have been shown 
to protect heart ischemic injury (Li et al 2004).
Conclusions
In conclusion, beta-glucans are potentially beneﬁ  cial in 
the treatment of diabetes and associated cardiovascular 
risks. Studies have shown that beta-glucans could reduce 
hyperglycemia, hyperlipidemia, and hypertension. Thus, 
beta-glucan could produce new approaches for the treatment 
of diabetes. However, no pure beta-glucan has been used. 
Thus, it is not known if other components in products used 
could also have effects. Beta-glucans are diverse in their 
structure and some may be not effective on diabetes. Thus, 
characterization of structure features essential for antidiabetic 
effects is of importance and the modiﬁ  cation of beta-glucan 
structure may lead to compounds that are more effective for 
the treatment of diabetes. Further studies will be also needed 
to elucidate how beta-glucan affect PI3K/Akt in diabetes.
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